Event Summary
The Life Sciences Supply Chain Resilience Forum, held on 24 and 25 February 2022, examined how the sector is reshaping operations in response to post-pandemic pressures, shifting risks, and rising expectations for end-to-end visibility. Speakers shared lessons from global manufacturers, with case studies on vaccine deployment, agile response models, digital transformation, and smarter inventory reporting across complex international networks. The discussions highlighted how organisations are strengthening resilience through data consolidation, integrated planning, and closer collaboration with external partners. The forum outlined clear priorities for future-ready supply chains that support stable delivery, informed decision-making, and long-term operational strength.
Key Topics
- Post Covid-19 outlook: rewriting the life sciences supply chain for resilience and agility
- Lessons learned from the pandemic and identifying future risks in supply chain operations
- Global inventory reporting and ERP consolidation for end-to-end visibility and efficiency
- Agility and resilience in vaccine development and distribution: Pfizer case study
- Transforming the end-to-end supply chain through digitalisation and Industry 4.0 strategies
- Leveraging blockchain, serialisation, and authentication to combat counterfeiting
- Resilient planning and scheduling: optimising people, processes, and materials across production and labs
- Digital transformation at Merck and Novartis: enabling end-to-end visibility and lean digital core operations
- Building sustainable, connected supply chains through real-time integration of internal and external data
- Future outlook for life sciences supply chains: emerging trends, potential disruptions, and technology investment strategies
Can’t find something?
We are always here to help. Please, contact us.
